TorS - Reframing a rational for type 2 diabetes treatment

Jacob Bar-Tana*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

The mammalian target of rapamycin complex 1 syndrome (Tors), paradigm implies an exhaustive cohesive disease entity driven by a hyperactive mTORC1, and which includes obesity, type 2 diabetic hyperglycemia, diabetic dyslipidemia, diabetic cardiomyopathy, diabetic nephropathy, diabetic peripheral neuropathy, hypertension, atherosclerotic cardiovascular disease, non-alcoholic fatty liver disease, some cancers, neurodegeneration, polycystic ovary syndrome, psoriasis and other. The TorS paradigm may account for the efficacy of standard-of-care treatments of type 2 diabetes (T2D) in alleviating the glycaemic and non-glycaemic diseases of TorS in T2D and non-T2D patients. The TorS paradigm may generate novel treatments for TorS diseases.

Original languageEnglish
Article numbere3712
JournalDiabetes/Metabolism Research and Reviews
Volume40
Issue number1
DOIs
StatePublished - Jan 2024

Bibliographical note

Publisher Copyright:
© 2023 The Authors. Diabetes/Metabolism Research and Reviews published by John Wiley & Sons Ltd.

Keywords

  • insulin
  • metabolic stress
  • metabolic syndrome (MetS)
  • mTORC1syndrome (TorS)
  • type 2 diabetes (T2D)

Fingerprint

Dive into the research topics of 'TorS - Reframing a rational for type 2 diabetes treatment'. Together they form a unique fingerprint.

Cite this